SAB Biotherapeutics

SAB Biotherapeutics wins BARDA MERS treatment contract

Monday, August 29, 2016

SAB Biotherapeutics, a clinical-stage biopharmaceutical development company, has been awarded a contract for up to $5.3 million by the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services (HHS). The funding will be used for advanced clinical manufacturing and testing for SAB’s novel antibody therapeutic (SAB-301) to treat MERS-CoV.

[Read More]